{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T10:00:26Z","timestamp":1768989626631,"version":"3.49.0"},"reference-count":73,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1097\/med.0b013e32835a000e","type":"journal-article","created":{"date-parts":[[2013,8,30]],"date-time":"2013-08-30T16:02:04Z","timestamp":1377878524000},"page":"512-519","source":"Crossref","is-referenced-by-count":21,"title":["Clinical update on screening, diagnosis and management of metabolic disorders and cardiovascular risk factors associated with polycystic ovary syndrome"],"prefix":"10.1097","volume":"19","author":[{"given":"Grace","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Coviello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-12-20211004","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1210\/jc.2003-032046","article-title":"The prevalence and features of the polycystic ovary syndrome in an unselected population.","volume":"89","author":"Azziz","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R2-12-20211004","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/humrep\/dep399","article-title":"The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria.","volume":"25","author":"March","year":"2010","journal-title":"Hum Reprod"},{"key":"R3-12-20211004","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199509283331307","article-title":"Polycystic ovary syndrome.","volume":"333","author":"Franks","year":"1995","journal-title":"N Engl J Med"},{"key":"R4-12-20211004","first-page":"365","article-title":"Polycystic ovary syndrome: syndrome XX Trends Endocrinol M","volume":"14","author":"Sam","year":"2003","journal-title":"etab"},{"key":"R6-12-20211004","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1440-1746.2008.05740.x","article-title":"An association between nonalcoholic fatty liver disease and polycystic ovarian syndrome.","volume":"24","author":"Brzozowska","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"R8-12-20211004","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.fertnstert.2003.10.004","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.","volume":"81","author":"Rotterdam","year":"2004","journal-title":"Fertil Steril"},{"key":"R9-12-20211004","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1210\/jc.2006-0178","article-title":"Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline.","volume":"91","author":"Azziz","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R10-12-20211004","doi-asserted-by":"crossref","first-page":"E868","DOI":"10.1210\/jc.2011-3357","article-title":"Relative Contributions of oligomenorrhea and hyperandrogenemia to the risk of metabolic syndrome in midlife women.","volume":"97","author":"Polotsky","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R11-12-20211004","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrendo.2010.217","article-title":"Polycystic ovary syndrome: etiology, pathogenesis and diagnosis.","volume":"7","author":"Goodarzi","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"R12-12-20211004","first-page":"126","article-title":"American Association of Clinical Endocrinologists position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome.","volume":"11","year":"2005","journal-title":"Endocr Pract"},{"key":"R13-12-20211004","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.fertnstert.2008.06.035","article-title":"The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report.","volume":"91","author":"Azziz","year":"2009","journal-title":"Fertil Steril"},{"key":"R14-12-20211004","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/humrep\/deh098","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).","volume":"19","year":"2004","journal-title":"Hum Reprod"},{"key":"R15-12-20211004","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1210\/jc.2009-2724","article-title":"Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society.","volume":"95","author":"Wild","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R16-12-20211004","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/01.OGX.0000109523.25076.E2","article-title":"Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls.","volume":"59","author":"Legro","year":"2004","journal-title":"Obstet Gynecol Surv"},{"key":"R17-12-20211004","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.molmed.2006.05.006","article-title":"Molecular mechanisms of insulin resistance in polycystic ovary syndrome.","volume":"12","author":"Diamanti-Kandarakis","year":"2006","journal-title":"Trends Mol Med"},{"key":"R18-12-20211004","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1210\/jc.2011-2939","article-title":"Hyperinsulinemia amplifies GnRH agonist stimulated ovarian steroid secretion in women with polycystic ovary syndrome.","volume":"97","author":"Tosi","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R19-12-20211004","doi-asserted-by":"crossref","first-page":"402052","DOI":"10.1155\/2011\/402052","article-title":"Pharmacological treatment of obesity in patients with polycystic ovary syndrome.","volume":"2011","author":"Kahal","year":"2011","journal-title":"J Obes"},{"key":"R20-12-20211004","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/humupd\/7.4.405","article-title":"Candidate genes in polycystic ovary syndrome.","volume":"7","author":"Franks","year":"2001","journal-title":"Hum Reprod Update"},{"key":"R21-12-20211004","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/humupd\/dmi025","article-title":"Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth.","volume":"11","author":"Diamanti-Kandarakis","year":"2005","journal-title":"Hum Reprod Update"},{"key":"R22-12-20211004","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/ncpendmet0400","article-title":"The genetics of the polycystic ovary syndrome.","volume":"3","author":"Urbanek","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"R23-12-20211004","doi-asserted-by":"crossref","first-page":"E765","DOI":"10.1210\/jc.2011-2377","article-title":"Abnormal expression of genes involved in inflammation, lipid metabolism, and wnt signaling in the adipose tissue of polycystic ovary syndrome.","volume":"97","author":"Chazenbalk","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R24-12-20211004","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/ng.732","article-title":"Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.","volume":"43","author":"Chen","year":"2011","journal-title":"3 Nat Genet"},{"key":"R25-12-20211004","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/jmedgenet-2011-100427","article-title":"Replication of association of DENND1A and THADA variants with polycystic ovary syndrome in European cohorts.","volume":"49","author":"Goodarzi","year":"2012","journal-title":"J Med Genet"},{"key":"R26-12-20211004","doi-asserted-by":"crossref","first-page":"E1342","DOI":"10.1210\/jc.2011-3478","article-title":"Variants in DENND1A are associated with polycystic ovary syndrome in women of European ancestry.","volume":"97","author":"Welt","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R27-12-20211004","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1055\/s-0031-1286279","article-title":"Susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21, and 9q333 in a cohort of Caucasian women.","volume":"43","author":"Lerchbaum","year":"2011","journal-title":"Horm Metab Res"},{"key":"R28-12-20211004","doi-asserted-by":"crossref","first-page":"e27286","DOI":"10.1371\/journal.pone.0027286","article-title":"Epigenetic mechanism underlying the development of polycystic ovary syndrome (PCOS)-like phenotypes in prenatally androgenized rhesus monkeys.","volume":"6","author":"Xu","year":"2011","journal-title":"PLoS One"},{"key":"R29-12-20211004","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1210\/jc.2005-2757","article-title":"Review: fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies.","volume":"91","author":"Xita","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R30-12-20211004","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.fertnstert.2009.10.020","article-title":"Epigenetics in polycystic ovary syndrome: a pilot study of global DNA methylation.","volume":"94","author":"Xu","year":"2010","journal-title":"Fertil Steril"},{"key":"R31-12-20211004","first-page":"948","article-title":"Major cardiovascular disease (CVD) during 1997-1999 and major CVD hospital discharge rates in 1997 among women with diabetes -- United States.","volume":"50","year":"2001","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R32-12-20211004","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.tem.2007.07.004","article-title":"Pathophysiology and types of dyslipidemia in PCOS.","volume":"18","author":"Diamanti-Kandarakis","year":"2007","journal-title":"Trends Endocrinol Metab"},{"key":"R33-12-20211004","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.fertnstert.2010.12.027","article-title":"Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis.","volume":"95","author":"Wild","year":"2011","journal-title":"Fertil Steril"},{"key":"R34-12-20211004","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pharmthera.2008.04.009","article-title":"Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights.","volume":"119","author":"Westerveld","year":"2008","journal-title":"Pharmacol Ther"},{"key":"R35-12-20211004","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.steroids.2011.12.002","article-title":"Dyslipidemia in PCOS.","volume":"77","author":"Wild","year":"2012","journal-title":"Steroids"},{"key":"R36-12-20211004","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3109\/09513590.2010.481025","article-title":"Atherogenic metabolic profile in PCOS patients: role of obesity and hyperandrogenism.","volume":"26","author":"Castelo-Branco","year":"2010","journal-title":"Gynecol Endocrinol"},{"key":"R37-12-20211004","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1210\/jc.2006-1988","article-title":"Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial.","volume":"92","author":"Banaszewska","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"R38-12-20211004","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1016\/j.fertnstert.2009.11.045","article-title":"Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study.","volume":"94","author":"Kazerooni","year":"2010","journal-title":"Fertil Steril"},{"key":"R40-12-20211004","doi-asserted-by":"crossref","first-page":"912","DOI":"10.2310\/JIM.0b013e31821bfd9c","article-title":"Simvastatin effects on androgens, inflammatory mediators, and endogenous pituitary gonadotropins among patients with PCOS undergoing IVF: results from a prospective, randomized, placebo-controlled clinical trial.","volume":"59","author":"Rashidi","year":"2011","journal-title":"J Investig Med"},{"key":"R41-12-20211004","first-page":"28","article-title":"How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome Am J Obstet G","volume":"198","author":"Rizzo","year":"2008","journal-title":"ynecol"},{"key":"R42-12-20211004","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1210\/jc.2003-031378","article-title":"Insulin sensitivity in women with polycystic ovary syndrome.","volume":"89","author":"Vrbikova","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"R43-12-20211004","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.fertnstert.2006.04.011","article-title":"Insulin resistance in women with polycystic ovary syndrome.","volume":"86","author":"Dunaif","year":"2006","journal-title":"Fertil Steril"},{"key":"R44-12-20211004","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1210\/jc.2011-1896","article-title":"Insulin resistance is a sufficient basis for hyperandrogenism in lipodystrophic women with polycystic ovarian syndrome.","volume":"97","author":"Lungu","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R45-12-20211004","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1210\/jc.2005-1329","article-title":"Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome.","volume":"91","author":"Ehrmann","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R46-12-20211004","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1210\/jc.2004-1045","article-title":"Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome.","volume":"90","author":"Apridonidze","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R47-12-20211004","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jc.2005-1666","article-title":"Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance.","volume":"91","author":"Coviello","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R48-12-20211004","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.fertnstert.2011.07.002","article-title":"Comparison of diabetes mellitus and insulin resistance screening methods for women with polycystic ovary syndrome.","volume":"96","author":"Hurd","year":"2011","journal-title":"Fertil Steril"},{"key":"R49-12-20211004","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/GCO.0b013e32833e1264","article-title":"Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update.","volume":"22","author":"Katsiki","year":"2010","journal-title":"Curr Opin Obstet Gynecol"},{"key":"R50-12-20211004","first-page":"16","article-title":"Effect of metformin and pioglitazone treatment on cardiovascular risk profile in polycystic ovary syndrome.","volume":"44","author":"Ziaee","year":"2012","journal-title":"Acta Med Indones"},{"key":"R51-12-20211004","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ejogrb.2010.12.041","article-title":"Effect of dose escalation of metformin on clinical features, insulin sensitivity and androgen profile in polycystic ovary syndrome.","volume":"156","author":"Yasmin","year":"2011","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R52-12-20211004","first-page":"714","article-title":"Metformin versus metformin plus rosiglitazone in women with polycystic ovary syndrome.","volume":"124","author":"Liao","year":"2011","journal-title":"Chin Med J (Engl)"},{"key":"R53-12-20211004","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.fertnstert.2010.06.058","article-title":"Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study.","volume":"95","author":"Naka","year":"2011","journal-title":"Fertil Steril"},{"key":"R54-12-20211004","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1210\/jc.2011-3061","article-title":"Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial.","volume":"97","author":"Morin-Papunen","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R55-12-20211004","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejogrb.2011.03.024","article-title":"The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications.","volume":"157","author":"De Leo","year":"2011","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R56-12-20211004","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1600-0412.2012.01385.x","article-title":"Pregnancy outcomes and the effect of metformin treatment in women with polycystic ovary syndrome: an overview.","volume":"91","author":"Ghazeeri","year":"2012","journal-title":"Acta Obstet Gynecol Scand"},{"key":"R57-12-20211004","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2265.2007.02742.x","article-title":"Quality of life and psychological morbidity in women with polycystic ovary syndrome: body mass index, age and the provision of patient information are significant modifiers.","volume":"66","author":"Ching","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R58-12-20211004","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ejogrb.2005.03.010","article-title":"Obesity and extreme obesity, manifest by ages 20-24 years, continuing through 32-41 years in women, should alert physicians to the diagnostic likelihood of polycystic ovary syndrome as a reversible underlying endocrinopathy.","volume":"122","author":"Glueck","year":"2005","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R59-12-20211004","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3109\/09513590.2011.589929","article-title":"Evaluation of body fat distribution in PCOS and its association with carotid atherosclerosis and insulin resistance.","volume":"28","author":"Karabulut","year":"2012","journal-title":"Gynecol Endocrinol"},{"key":"R60-12-20211004","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1210\/jc.2011-1609","article-title":"Effect of lifestyle intervention on features of polycystic ovarian syndrome, metabolic syndrome, and intima-media thickness in obese adolescent girls.","volume":"96","author":"Lass","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R61-12-20211004","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.fertnstert.2003.08.023","article-title":"A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome.","volume":"81","author":"Stamets","year":"2004","journal-title":"Fertil Steril"},{"key":"R62-12-20211004","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.fertnstert.2008.09.018","article-title":"Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society.","volume":"92","author":"Moran","year":"2009","journal-title":"Fertil Steril"},{"key":"R63-12-20211004","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/humupd\/dmq045","article-title":"Exercise therapy in polycystic ovary syndrome: a systematic review.","volume":"17","author":"Harrison","year":"2011","journal-title":"Hum Reprod Update"},{"key":"R64-12-20211004","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.1210\/jc.2005-1490","article-title":"The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery.","volume":"90","author":"Escobar-Morreale","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R65-12-20211004","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3748\/wjg.14.185","article-title":"Nonalcoholic fatty liver disease and the metabolic syndrome: an update.","volume":"14","author":"Rector","year":"2008","journal-title":"World J Gastroenterol"},{"key":"R66-12-20211004","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1210\/jc.2005-2774","article-title":"Nonalcoholic steatohepatitis and nonalcoholic fatty liver disease in young women with polycystic ovary syndrome.","volume":"91","author":"Setji","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R67-12-20211004","doi-asserted-by":"crossref","first-page":"199","DOI":"10.14310\/horm.2002.1236","article-title":"In overweightobese but not in normal-weight women, polycystic ovary syndrome is associated with elevated liver enzymes compared to controls.","volume":"8","author":"Economou","year":"2009","journal-title":"Hormones (Athens)"},{"key":"R68-12-20211004","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/humrep\/dep380","article-title":"Increased androgen bioavailability is associated with nonalcoholic fatty liver disease in women with polycystic ovary syndrome.","volume":"25","author":"Vassilatou","year":"2010","journal-title":"Hum Reprod"},{"key":"R69-12-20211004","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1665-2681(19)31616-3","article-title":"Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens.","volume":"9","author":"Gutierrez-Grobe","year":"2010","journal-title":"Ann Hepatol"},{"key":"R70-12-20211004","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1053\/j.gastro.2012.04.001","article-title":"The Diagnosis and management of nonalcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology.","volume":"142","author":"Chalasani","year":"2012","journal-title":"Gastroenterology"},{"key":"R71-12-20211004","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3109\/09513591003686304","article-title":"Current evidence of acupuncture on polycystic ovarian syndrome.","volume":"26","author":"Lim","year":"2010","journal-title":"Gynecol Endocrinol"},{"key":"R72-12-20211004","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1152\/ajpendo.00667.2010","article-title":"The physiological basis of complementary and alternative medicines for polycystic ovary syndrome.","volume":"301","author":"Raja-Khan","year":"2011","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R73-12-20211004","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/humupd\/dmr025","article-title":"Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome.","volume":"17","author":"Toulis","year":"2011","journal-title":"Hum Reprod Update"},{"key":"R74-12-20211004","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.atherosclerosis.2005.10.007","article-title":"Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives.","volume":"185","author":"Cussons","year":"2006","journal-title":"Atherosclerosis"},{"key":"R75-12-20211004","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1210\/jc.2011-1677","article-title":"Cardiovascular disease and risk factors in PCOS women of postmenopausal age: a 21-year controlled follow-up study.","volume":"96","author":"Schmidt","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R76-12-20211004","first-page":"302","article-title":"Polycystic ovary syndrome and cardiovascular disease: a premature association Endocr R","volume":"24","author":"Legro","year":"2003","journal-title":"ev"}],"container-title":["Current Opinion in Endocrinology, Diabetes & Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01266029-201212000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T02:19:59Z","timestamp":1633313999000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01266029-201212000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":73,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/med.0b013e32835a000e","relation":{},"ISSN":["1752-296X"],"issn-type":[{"value":"1752-296X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}